Login to Your Account



Rib-X Raises $51M To Push Ribosome-Based Antibiotics

By Aaron Lorenzo


Friday, May 2, 2003
Rib-X Pharmaceuticals Inc. landed the year s third-largest private round of financing, reeling in $51 million in a Series B placement of preferred stock.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription